In the Claims:

1-15. (Canceled)

16. (Currently Amended) A compound of formula (I)



(I)

wherein

---- represents a single or a double bond;

R is a radical selected from:



i) ii) iii) and iv)

in which R_1 is halogen, cyano, C_{1-4} alkyl, C_{1-4} alkoxy, trifluoromethyl or trifluoromethoxy and p is zero or an integer from 1 to 3;

R_2 is hydrogen or C_{1-4} alkyl;

R_3 is hydrogen, hydroxy or C_{1-4} alkyl;

R_4 is hydrogen or R_4 together with R_3 is =O or $=CH_2$;

R_5 is phenyl, naphthyl, a 9 to 10 membered fused bicyclic heterocyclic group or a 5 or 6 membered heteroaryl group, wherein said groups are optionally substituted by 1 to 3 groups independently selected from trifluoromethyl, C_{1-4} alkyl, hydroxy, cyano, C_{1-4} alkoxy, trifluoromethoxy, halogen or $S(O)_qC_{1-4}$ alkyl;

R_6 and R_7 independently are hydrogen, cyano, C_{1-4} alkyl;

R_8 is $(CH_2)_rR_{10}$;

R_9 is hydrogen, halogen, C_{3-7} cycloalkyl, hydroxy, nitro, cyano or C_{1-4} alkyl optionally substituted by one or two groups selected from halogen, cyano, hydroxy or C_{1-4} alkoxy;

R_{10} is hydrogen or C_{3-7} cycloalkyl;

n is [[1 or]] 2;

q is 0, 1 or 2;

r is 0 or an integer from 1 to 4;

or a pharmaceutically acceptable salt ~~or a solvate~~ thereof.

17. (Canceled).

18. (Previously Presented) A compound as claimed in claim 1 wherein R is:



wherein R_1 is halogen, C_{1-4} alkyl, cyano, C_{1-4} alkoxy, trifluoromethyl or trifluoromethoxy and p is zero or an integer from 1 to 3.

19. (Previously Presented) A compound as claimed in claim 1 wherein R_5 is phenyl or naphthyl optionally substituted by one or two groups selected from trifluoromethyl, cyano, C_{1-4} alkyl or halogen.

20. (Previously Presented) A compound as claimed claim 1 wherein R_8 is $(CH_2)_rR_{10}$ wherein R_{10} is hydrogen or C_{3-7} cycloalkyl and r is 0 or 1.

21. (Previously Presented) A compound as claimed in claim 1, wherein R_9 is hydrogen or C_{1-4} alkyl optionally substituted by one or two halogens.

22. (Currently Amended) A compound as claimed in claim 1 wherein:

R is phenyl substituted by a fluorine;

R_2, R_9 and R_4 are each hydrogen;

R_3 is hydrogen, hydroxy or methyl, or R_3 together with R_4 is =O or $=CH_2$;

R_6 and R_7 are independently hydrogen or methyl;

R_5 is phenyl or naphthyl optionally substituted by one or two groups independently selected from cyano, methyl, chlorine, bromine or fluorine atom; and

R_8 is hydrogen, methyl or cyclopropylmethyl~~; and~~

~~n is 2~~.

23. (Currently Amended) A compound selected from:

1-[(3,5-Dichlorophenyl)methyl]-3-[4-(4-fluorophenyl)-4-piperidinyl]-1,5-dihydro-2*H*-pyrrol-2-one;

1-[(3,5-Dichlorophenyl)methyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-1,5-dihydro-2*H*-pyrrol-2-one ;

1-[1-(3,5-Dichlorophenyl)ethyl]-3-[4-(4-fluorophenyl)-4-piperidinyl]-1,5-dihydro-2*H*-pyrrol-2-one (Chain Enantiomer 1);

1-[(1*S*)-1-(3-Chloro-1-naphthalenyl)ethyl]-3-[4-(4-fluorophenyl)-4-piperidinyl]-1,5-dihydro-2*H*-pyrrol-2-one ;

1-[(3-Chloro-1-naphthalenyl)methyl]-3-[4-(4-fluorophenyl)-4-piperidinyl]-1,5-dihydro-2*H*-pyrrol-2-one;

4-({3-[4-(4-Fluorophenyl)-4-piperidinyl]-2-oxo-2,5-dihydro-1*H*-pyrrol-1-yl}methyl)-2-naphthalenecarbonitrile;

1-[1-(3,5-Dichlorophenyl)ethyl]-3-[4-(4-fluorophenyl)-4-piperidinyl]-1,5-dihydro-2*H*-pyrrol-2-one (Chain Enantiomer 2);

1-[(1*R*)-1-(3-Chloro-1-naphthalenyl)ethyl]-3-[4-(4-fluorophenyl)-4-piperidinyl]-1,5-dihydro-2*H*-pyrrol-2-one;

1-[1-(3,5-Dichlorophenyl)ethyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-1,5-dihydro-2*H*-pyrrol-2-one (Chain Enantiomer 1);

1-[(1*S*)-1-(3-Chloro-1-naphthalenyl)ethyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-1,5-dihydro-2*H*-pyrrol-2-one ;

1-[(3-Chloro-1-naphthalenyl)methyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-1,5-dihydro-2*H*-pyrrol-2-one;

1-[1-(3,5-Dichlorophenyl)ethyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-1,5-dihydro-2*H*-pyrrol-2-one (Chain Enantiomer 2);

1-[(1*R*)-1-(3-Chloro-1-naphthalenyl)ethyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-1,5-dihydro-2*H*-pyrrol-2-one;

4-({3-[4-(4-Fluorophenyl)-1-methyl-4-piperidinyl]-2-oxo-2,5-dihydro-1*H*-pyrrol-1-yl}methyl)-2-naphthalenecarbonitrile;

1-[1-(3,5-Dichlorophenyl)ethyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-1,5-dihydro-2*H*-pyrrol-2-one hydrochloride (Chain Enantiomer 1);

1-[1-(3,5-Dichlorophenyl)ethyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-1,5-dihydro-2*H*-pyrrol-2-one hydrochloride (Chain Enantiomer 1);

1-[(3-Chloro-1-naphthalenyl)methyl]-3-[1-(cyclopropylmethyl)-4-(4-fluorophenyl)-4-piperidinyl]-1,5-dihydro-2*H*-pyrrol-2-one;

1-[(3,5-Dichlorophenyl)methyl]-3-[4-(4-fluorophenyl)-4-piperidinyl]-2-pyrrolidinone

1-[(1*S*)-1-(3-Chloro-1-naphthalenyl)ethyl]-3-[4-(4-fluorophenyl)-4-piperidinyl]-2-pyrrolidinone (Diastereoisomer 1);

1-[(1*S*)-1-(3-Chloro-1-naphthalenyl)ethyl]-3-[4-(4-fluorophenyl)-4-piperidinyl]-2-pyrrolidinone;

1-[1-(3,5-Dichlorophenyl)ethyl]-3-[4-(4-fluorophenyl)-4-piperidinyl]-2-pyrrolidinone (Diastereoisomer 1 Chain Enantiomer 1);

1-[1-(3,5-Dichlorophenyl)ethyl]-3-[4-(4-fluorophenyl)-4-piperidinyl]-2-pyrrolidinone (Diastereoisomer 2 Chain Enantiomer 1);

1-[1-(3,5-Dichlorophenyl)ethyl]-3-[4-(4-fluorophenyl)-4-piperidinyl]-2-pyrrolidinone (Diastereoisomer 1 Chain Enantiomer 2);

1-[1-(3,5-Dichlorophenyl)ethyl]-3-[4-(4-fluorophenyl)-4-piperidinyl]-2-pyrrolidinone (Diastereoisomer 2 Chain Enantiomer 2);

4-({3-[4-(4-Fluorophenyl)-4-piperidinyl]-2-oxo-1-pyrrolidinyl}methyl)-2-naphthalenecarbonitrile (Enantiomer 1);

4-({3-[4-(4-Fluorophenyl)-4-piperidinyl]-2-oxo-1-pyrrolidinyl}methyl)-2-naphthalenecarbonitrile (Enantiomer 2);

7-Fluoro-4-({3-[4-(4-fluorophenyl)-4-piperidinyl]-2-oxo-1-pyrrolidinyl}methyl)-2-naphthalenecarbonitrile (Enantiomer 2);

6-Fluoro-4-({3-[4-(4-fluorophenyl)-4-piperidinyl]-2-oxo-1-pyrrolidinyl}methyl)-2-naphthalenecarbonitrile (Enantiomer 2);

7-Fluoro-4-({3-[4-(4-fluorophenyl)-4-piperidinyl]-2-oxo-1-pyrrolidinyl}methyl)-2-naphthalenecarbonitrile (Enantiomer 1);

6-Fluoro-4-({3-[4-(4-fluorophenyl)-4-piperidinyl]-2-oxo-1-pyrrolidinyl}methyl)-2-naphthalenecarbonitrile (Enantiomer 1);

1-[(3,5-Dichlorophenyl)methyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-2-pyrrolidinone;

1-[1-(3-Chloro-1-naphthalenyl)ethyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-2-pyrrolidinone (Diastereoisomer 2 Chain Enantiomer 1);

1-[1-(3,5-Dichlorophenyl)ethyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-2-pyrrolidinone (Diastereoisomer 1 Chain Enantiomer 1);

1-[1-(3,5-Dichlorophenyl)ethyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-2-pyrrolidinone (Diastereoisomer 2 Chain Enantiomer 1);

1-[1-(3,5-Dichlorophenyl)ethyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-2-pyrrolidinone (Diastereoisomer 1 Chain Enantiomer 2);

1-[1-(3,5-Dichlorophenyl)ethyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-2-pyrrolidinone (Diastereoisomer 2 Chain Enantiomer 2);

1-[(3,5-Dichlorophenyl)methyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-2-pyrrolidinone (Enantiomer 1);

1-[(3,5-Dichlorophenyl)methyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-2-pyrrolidinone (Enantiomer 2);

4-({3-[4-(4-Fluorophenyl)-1-methyl-4-piperidinyl]-2-oxo-1-pyrrolidinyl}methyl)-2-naphthalenecarbonitrile (Enantiomer 1);

4-({3-[4-(4-Fluorophenyl)-1-methyl-4-piperidinyl]-2-oxo-1-pyrrolidinyl}methyl)-2-naphthalenecarbonitrile (Enantiomer 2);

7-Fluoro-4-({3-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-2-oxo-1-pyrrolidinyl}methyl)-2-naphthalenecarbonitrile (Enantiomer 2);

6-Fluoro-4-({3-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-2-oxo-1-pyrrolidinyl}methyl)-2-naphthalenecarbonitrile;

7-Fluoro-4-({3-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-2-oxo-1-pyrrolidinyl}methyl)-2-naphthalenecarbonitrile (Enantiomer 1);

6-Fluoro-4-({3-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-2-oxo-1-pyrrolidinyl}methyl)-2-naphthalenecarbonitrile (Enantiomer 1);

1-[(3,5-Dichlorophenyl)methyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-1*H*-pyrrole-2,5-dione;

1-[(3,5-Dichlorophenyl)methyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-5-methylidene-1,5-dihydro-2*H*-pyrrol-2-one;

and phamaceutically acceptable salts ~~or solvates~~ thereof.

24. (Previously Presented) A compound according to claim 23 in amorphous or crystalline form.

25. (Previously Presented) A compound selected from:

1-[(3,5-Dichlorophenyl)methyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-1,5-dihydro-2*H*-pyrrol-2-one;

1-[(3,5-Dichlorophenyl)methyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-1,5-dihydro-2*H*-pyrrol-2-one hydrochloride;

1-[(3,5-Dichlorophenyl)methyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-1,5-dihydro-2*H*-pyrrol-2-one fumarate;

1-[(3,5-Dichlorophenyl)methyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-1,5-dihydro-2*H*-pyrrol-2-one citrate.

26. (Previously Presented) A compound according to claim 25 in crystalline form.

27. (Previously Presented) 1-[(3,5-Dichlorophenyl)methyl]-3-[4-(4-fluorophenyl)-1-methyl-4-piperidinyl]-1,5-dihydro-2*H*-pyrrol-2-one citrate.

28. (Previously Presented) 1-[(3,5-Dichlorophenyl)methyl]-3-[4-(4-fluorophenyl)-4-piperidinyl]-1,5-dihydro-2*H*-pyrrol-2-one.

29. (Previously Presented) A pharmaceutical composition comprising a compound as claimed in claim 1 in admixture with one or more pharmaceutically acceptable carriers or excipients.

30. (Previously Presented) A pharmaceutical composition comprising a compound as claimed in claim 25 in admixture with one or more pharmaceutically acceptable carriers or excipients.

31. (Previously Presented) A pharmaceutical composition comprising a compound as claimed in claim 28 in admixture with one or more pharmaceutically acceptable carriers or excipients.

32. - 37. (Canceled).

38. (Previously Presented) 1-[(3,5-Dichlorophenyl)methyl]-3-[4-(4-fluorophenyl)-4-piperidinyl]-1,5-dihydro-2*H*-pyrrol-2-one or a pharmaceutically acceptable salt or a solvate thereof.

39. (Previously Presented) A hydrochloride salt of the compound according to claim 38.

40. (Previously Presented) A fumarate salt of the compound according to claim 38.

41. (Previously Presented) A citrate salt of the compound according to claim 38.

42. (Previously Presented) A citrate salt according to claim 41, having a crystal form with x-ray powder diffraction pattern with d spacings as follows:

Two theta (deg)	d-spacing (Angstroms)
7,1	12,5
10,6	8,4
11,6	7,7
11,9	7,4
14,0	6,3
14,5	6,1
16,0	5,5
16,8	5,3
17,6	5,0
18,5	4,8
19,5	4,6
19,9	4,5
20,6	4,3
21,2	4,2
21,8	4,1
22,4	4,0
23,1	3,9
23,6	3,8

Two theta (deg)	d-spacing (Angstroms)
24,0	3,7
24,9	3,6
25,5	3,5
26,4	3,4
28,1	3,2
29,1	3,1
29,7	3,0
32,9	2,7

43. (Previously Presented) A citrate salt according to claim 41, having a crystal form with x-ray powder diffraction pattern with d spacings as follows:

d spacing Angstroms	Two Theta (deg)
7,7	11,5
7,2	12,2
5,5	16,1
5,3	16,7
5,0	17,6
4,8	18,6
4,6	19,4
4,2	21,1
3,9	23,1
3,8	23,6
3,6	24,5

44. (Previously Presented) A crystalline hydrate of the compound according to claim 38.